Positive Press Coverage Somewhat Unlikely to Impact Ascendis Pharma A/S (ASND) Share Price

Media headlines about Ascendis Pharma A/S (NASDAQ:ASND) have trended positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.8796109280509 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Ascendis Pharma A/S (NASDAQ:ASND) opened at $64.32 on Monday. The firm has a market capitalization of $2,670.82, a P/E ratio of -17.67 and a beta of 0.68. Ascendis Pharma A/S has a 12-month low of $21.95 and a 12-month high of $69.00.

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 21st. Credit Suisse Group raised their price objective on Ascendis Pharma A/S from $50.00 to $78.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 20th. Zacks Investment Research upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Wedbush reiterated an “outperform” rating and set a $62.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 6th. Finally, BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $59.83.

TRADEMARK VIOLATION WARNING: “Positive Press Coverage Somewhat Unlikely to Impact Ascendis Pharma A/S (ASND) Share Price” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3300902/positive-press-coverage-somewhat-unlikely-to-impact-ascendis-pharma-a-s-asnd-share-price.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Insider Buying and Selling by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Atlantic Capital  Receiving Somewhat Favorable Press Coverage, Accern Reports
Atlantic Capital Receiving Somewhat Favorable Press Coverage, Accern Reports
Foresight Energy  Receives Daily Media Sentiment Rating of -0.02
Foresight Energy Receives Daily Media Sentiment Rating of -0.02
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio Stock Price
Ribbon Communications Inc  Receives $7.56 Consensus PT from Analysts
Ribbon Communications Inc Receives $7.56 Consensus PT from Analysts
Analysts Set Progressive Co.  Price Target at $53.43
Analysts Set Progressive Co. Price Target at $53.43
Brokerages Set Fortune Brands Home & Security  Target Price at $73.62
Brokerages Set Fortune Brands Home & Security Target Price at $73.62


© 2006-2018 Ticker Report. Google+.